Trentham D E, Le C H
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Ann Intern Med. 1998 Jul 15;129(2):114-22. doi: 10.7326/0003-4819-129-2-199807150-00011.
Relapsing polychondritis, an uncommon, chronic, multisystem disorder characterized by recurrent episodes of inflammation of cartilaginous tissues, can be life-threatening, debilitating, and difficult to diagnose. This review is based on the authors' experience with 36 patients with relapsing polychondritis who were followed from 1980 to 1997, 30 patients located elsewhere who completed a detailed questionnaire and interview, and a perusal of English-language textbooks and papers located by a systematic search of the MEDLINE database. Relapsing polychondritis can present in a highly ambiguous fashion; therefore, in the authors' series, the mean delay from the time medical attention was sought because of symptom onset until diagnosis was 2.9 years. Although prednisone was the main form of treatment, methotrexate seemed to be of additional value. Survival was much more favorable than previously thought. Greater awareness of relapsing polychondritis would probably lead to earlier diagnosis and better outcomes.
复发性多软骨炎是一种罕见的慢性多系统疾病,其特征为软骨组织反复发生炎症,可危及生命、使人衰弱且难以诊断。本综述基于作者对1980年至1997年间随访的36例复发性多软骨炎患者、其他地区完成详细问卷和访谈的30例患者的经验,以及通过系统检索MEDLINE数据库找到的英文教科书和论文。复发性多软骨炎的表现可能非常不明确;因此,在作者的系列研究中,从因症状发作寻求医疗关注到诊断的平均延迟时间为2.9年。虽然泼尼松是主要的治疗形式,但甲氨蝶呤似乎具有额外的价值。生存率比以前认为的要好得多。对复发性多软骨炎有更高的认识可能会导致更早的诊断和更好的结果。